Company Description
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses.
Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers.
In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers.
The company was incorporated in 2015 and is headquartered in Houston, Texas.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jun 2, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Walter V. Klemp |
Contact Details
Address: 5300 Memorial Drive, Suite 950 Houston, Texas 77007 United States | |
| Phone | 713-300-5160 |
| Website | moleculin.com |
Stock Details
| Ticker Symbol | MBRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001659617 |
| CUSIP Number | 60855D200 |
| ISIN Number | US60855D2009 |
| Employer ID | 47-4671997 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Walter V. Klemp | Founder, Chairman, President and Chief Executive Officer |
| Jonathan P. Foster CPA | Executive Vice President and Chief Financial Officer |
| Dr. Donald H. Picker Ph.D. | Chief Scientific Officer |
| Dr. Waldemar Priebe Ph.D. | Co-Founder, Founding Scientist and Chairman of Scientific Advisory Board |
| Dr. Robert C. Shepard FACP, M.D. | Chief Medical Officer of Annamycin |
| Dr. John Paul Waymack M.D., Sc.D. | Senior Chief Medical Officer |
| Dr. Sandra L. Silberman M.D., Ph.D. | Chief Medical Officer of New Products |
| Dr. Wolfram C. M. Dempke M.B.A., M.D., Ph.D. | European Chief Medical Officer |
| Jacqueline Northcut | Consultant |
| Louis Ploth Jr. | Independent Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | 8-K | Current Report |
| Apr 18, 2024 | 8-K | Current Report |
| Apr 10, 2024 | 8-K | Current Report |
| Apr 8, 2024 | 8-K | Current Report |
| Mar 27, 2024 | 8-K | Current Report |
| Mar 25, 2024 | 8-K | Current Report |
| Mar 25, 2024 | 8-K | Current Report |
| Mar 22, 2024 | 8-K | Current Report |
| Mar 22, 2024 | 10-K | Annual Report |
| Mar 20, 2024 | 8-K | Current Report |